Type I PRMT generate ADMA, while Type II PRMT catalyzes the production of SDMA.[46] PRMTs play an important role in epigenetic regulation; however, overexpression of PRMTs is linked to poor prognosis of various cancers.[46] Particularly, PRMT5 is overexpressed in a variety of tumors and has been considered the target for the anti‐tumor therapy strategy.[50] In clinical trials, GSK3326595, a PRMT5 inhibitor, has been evaluated in breast cancer (NCT04676516) (Table 1). The gene discussed is PRMT5; the disease is neoplasm.